| Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (660kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-750863
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.75086
Zusammenfassung
A considerable number of patients with chronic inflammatory bowel diseases (IBD) are required to manage extensive polypharmaceutical regimes, which significantly elevates the risk of drug–drug interactions. Also, the disease’s impact often leads to the consumption of additional self-medication by the patients such as naturopathic remedies to alleviate disease-induced suffering and nutritional ...

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

Downloadstatistik